Join Dr. Michelle Sprout as she defines and reviews biological, biosimilars, and interchangeable products which are the fastest-growing class of therapeutic products in the U.S. and account for a substantial portion of health care costs. While awareness of biosimilars is high among healthcare providers, knowledge about the fundamentals of biosimilars is still lacking. This presentation will provide introductory information on biosimilars including but not limited to common terminology and definitions, insight into the approval process, as well as discussion around opportunities and challenges for biosimilar use.
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for insuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
Requirements for CE Credit
To claim credit for these sessions, participants must complete the following for each session (with a unique UAN):
- Visit this site. Make sure you are logged in and registered before proceeding.
- Complete an evaluation by clicking the green evaluation button for each session/block.
- Enter the evaluation code that was given to you at the end of the session you attended.
- Answer all questions honestly - we appreciate your feedback! All responses are stored anonymously.
- Click submit. As soon as you submit, a report containing the NABP ePID and DOB stored in your profile will be automatically sent to CPE Monitor.
- Please allow up to 48 hours for processing. Your credit should appear in your NABP profile online.
This session I will define and review information on biologics, biosimilars, and interchangeable products. Review how biologics and biosimilars differ form small molecule drugs and their generics. Discuss the approval process for biosimilars as well as the opportunities and challenges they present. At the end of this session my goal is for the audience to have a basic understanding about the fundamentals of biosimilars to help continue to educate themselves and patients as biosimilars continue to come to market.
- Define biosimilars and differentiate them from small molecule drugs and generic products
- Discuss the approval process for biosimilars
- Identify potential challenges related to the use of biosimilars
Michelle Sproat, Pharm.D.
Release Date: Mar 5, 2021
Credit Expiration Date: Feb 10, 2024